Journal of Internal Medicine · 2017 · 61 citations · 35 references
Public HealthPreventive MedicineBehavioral EpidemiologyEpidemiologyRisk AssessmentDiabetes PreventionTobacco EpidemiologyTobacco UseTobacco Use PreventionTobacco Use Risk AssessmentAlcohol Consumption PatternsNicotine Exposure EffectsPatient RegistriesPooled Hazard RatiosSmoking EpidemiologyTobacco Use Screening
BACKGROUND: Smoking and nicotine exposure increase insulin resistance and the risk of type 2 diabetes. Swedish smokeless tobacco (snus) is high in nicotine, and its use is prevalent in Scandinavian countries, but few studies have investigated snus use in relation to diabetes risk. OBJECTIVE: To explore the association between snus use and risk of type 2 diabetes using pooled data from five cohorts. METHODS: Analyses were based on prospective studies conducted between 1990 and 2013 including 54 531 never-smoking men and 2441 incident cases of type 2 diabetes identified through screening, self-reporting and hospital and prescription registries. Hazard ratios (HRs) and 95% confidence intervals (CIs) were assessed and adjusted for age, body mass index, educational level, alcohol consumption and physical activity. RESULTS: Compared to never users, the HR of type 2 diabetes was 1.15 (95% CI: 1.00-1.32) in current users of snus. In individuals consuming 5-6 boxes per week, the HR was 1.42 (95% CI: 1.07-1.87); in those consuming ≥7 boxes per week, the HR was 1.68 (95% CI: 1.17-2.41). Each additional box of snus consumed per week yielded an HR of 1.08 (95% CI: 1.01-1.16). CONCLUSION: Our findings indicate that high consumption of snus is a risk factor for type 2 diabetes. The risk was similar to that in smokers, implying that smokers will not reduce their risk of type 2 diabetes by changing to snus use. The results also support the notion that nicotine increases the risk of type 2 diabetes.
35
External review and validation of the Swedish national inpatient register
Jonas F. Ludvigsson, Eva Andersson, Anders Ekbom et al. · BMC Public Health · 2011 · 5.1K citations · Full text
Björn Wettermark, Niklas Hammar, C. MichaelFored et al. · Pharmacoepidemiology and Drug Safety · 2006 · 1.9K citations · Full text
The Västerbotten Intervention Programme: background, design and implications
Margareta Norberg, Stig Wall, Kurt Boman et al. · Global Health Action · 2010 · 366 citations · Full text